Updated Jul 16, 2026
FORD KATHLEEN has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $183K.
Kathleen Ford is the Chief Operating Officer at Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment. She has been involved in the company through multiple SEC filings, indicating her active role in the organization.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-20 | KURA | Kura Oncology, Inc. | S — Open-market sale | 2.3K | $9.08 | $20K |
| 2026-01-28 | KURA | Kura Oncology, Inc. | S — Open-market sale | 1.8K | $8.46 | $15K |
| 2026-01-06 | KURA | Kura Oncology, Inc. | A — Grant or award | 50.0K | $0.00 | |
| 2025-11-15 | KURA | Kura Oncology, Inc. | S — Open-market sale | 6.9K | $11.18 | $77K |
| 2025-11-15 | KURA | Kura Oncology, Inc. | A — Grant or award | 48.9K | $0.00 | |
| 2025-09-27 | KURA | Kura Oncology, Inc. | S — Open-market sale | 6.9K | $8.94 | $62K |
| 2025-09-27 | KURA | Kura Oncology, Inc. | A — Grant or award | 48.9K | $0.00 | |
| 2024-11-19 | KURA | Kura Oncology, Inc. | S — Open-market sale | 526 | $16.03 | $8K |
Kathleen Ford is the Chief Operating Officer at Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment. She has been involved in the company through multiple SEC filings, indicating her active role in the organization.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($183K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live FORD KATHLEEN profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.